Denosumab biosimilar(Fresenius Kabi)

地舒单抗生物类似药 (Fresenius Kabi)

Report date: 2025/04/01 17:32:00

Base Information

Drug NameDenosumab biosimilar(Fresenius Kabi)
Drug Alias NameBOMYNTRACONEXXENCEFKS-518
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesHypercalcemiaBone Resorption +[7] 
Global Approved IndicationsBone metastasesHypercalcemiaNeoplasms, Bone Tissue +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/03/25
Country/TerritoryCzechiaBulgariaUnited States +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFresenius Kabi Swissbiosim Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesFresenius Kabi Usa LlcFresenius Kabi Swissbiosim GmbhFresenius Kabi Deutschland Gmbh
Inactive CompaniesN/A
Active IndicationsBone metastasesHypercalcemiaBone Resorption +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A